Transitioning from Triamterene/HCTZ (Dyazide) to Valsartan + Furosemide

Initial Dosing Recommendations

Valsartan: Begin with 20 mg–40 mg once daily for most patients switching from a low‑intensity diuretic regimen; lower dose is preferred when baseline blood pressure is borderline or hypotension is a concern. [1 – American Heart Association]
Furosemide: Start with 20 mg–40 mg once daily. This dose provides a diuretic effect roughly equivalent to the 25 mg hydrochlorothiazide component of Dyazide in patients who were previously well‑controlled. [2 – American College of Cardiology]
Volume‑overloaded or heart‑failure patients: Consider initiating furosemide at 40 mg once daily to address greater fluid burden. [2 – American College of Cardiology]

Valsartan titration: Increase the dose every 1–2 weeks based on blood‑pressure response, aiming for 80 mg–160 mg once daily in isolated hypertension and up to 160 mg twice daily in heart‑failure indications. [1 – American Heart Association; 4 – American College of Cardiology]
Furosemide titration: Adjust the dose according to daily weight changes and clinical volume status; typical outpatient ceiling is 80 mg once or twice daily, although doses up to 600 mg daily may be required in severe refractory congestion. [2 – American College of Cardiology; 3 – American Heart Association]

Blood pressure, renal function (creatinine), and electrolytes (especially potassium) should be re‑checked within the first 1–2 weeks after therapy initiation. [1 – American Heart Association; 5 – European Society of Cardiology]
Daily weight tracking is recommended to gauge diuretic adequacy and guide furosemide dose adjustments. [2 – American College of Cardiology; 3 – American Heart Association]
Watch for symptomatic hypotension during the initial days, particularly when both agents are started. [1 – American Heart Association]

Electrolytes and renal function are re‑evaluated at 3 months and subsequently every 6 months. [5 – European Society of Cardiology]
Potassium surveillance is critical because switching from the potassium‑sparing triamterene to a potassium‑wasting loop diuretic can precipitate hypokalemia; supplement potassium only if levels fall below 3.5 mmol/L. [5 – European Society of Cardiology; 3 – American Heart Association]

Initiate valsartan at 40 mg twice daily, then uptitrate to 80 mg and finally 160 mg twice daily as tolerated. [1 – American Heart Association]
Tailor furosemide dosing to eliminate signs of fluid retention, using the titration principles above. [2 – American College of Cardiology; 3 – American Heart Association]

Start valsartan at 80 mg once daily (or 40 mg if hypotension risk exists). [1 – American Heart Association]
A furosemide dose of 20 mg–40 mg once daily is usually sufficient. [3 – American Heart Association]

Begin valsartan at 20 mg twice daily and uptitrate to the target of 160 mg twice daily. [1 – American Heart Association]

Avoid valsartan in patients with systolic BP < 90 mmHg, serum creatinine > 150 µmol/L, serum sodium < 135 mmol/L, or a history of angioedema. [1 – American Heart Association; 5 – European Society of Cardiology]
Monitor for opposing potassium effects: valsartan may cause hyper‑kalaemia, whereas furosemide predisposes to hypokalaemia. [1 – American Heart Association]
Avoid concurrent NSAIDs because they diminish diuretic efficacy and increase the risk of renal dysfunction. [5 – European Society of Cardiology]

Do not start both agents at high doses simultaneously, as this raises the risk of hypotension and acute kidney injury. [1 – American Heart Association; 5 – European Society of Cardiology]
Do not assume equivalent potency between furosemide and hydrochlorothiazide on a milligram basis; furosemide is more potent but has a shorter duration of action. [2 – American College of Cardiology; 3 – American Heart Association]
Do not neglect potassium monitoring after switching from a potassium‑sparing to a potassium‑wasting diuretic. [5 – European Society of Cardiology; 3 – American Heart Association]
Do not add potassium supplements prophylactically unless hypokalaemia develops, given valsartan’s intrinsic potassium‑retaining properties. [1 – American Heart Association]